Logo

Servier's Asparlas (calaspargase pegol-mknl) Receives FDA's Approval for Acute Lymphoblastic Leukemia (ALL)

Share this
Servier's Asparlas (calaspargase pegol-mknl) Receives FDA's Approval for Acute Lymphoblastic Leukemia (ALL)

Servier's Asparlas (calaspargase pegol-mknl) Receives FDA's Approval for Acute Lymphoblastic Leukemia (ALL)

Shots:

  • The approval is based on study assessing Asparlas (2500 U/m2- IV- q3w) in combination with multiagent chemotherapy in 124 patients with B-cell lineage ALL
  • The study resulted in achievement and maintenance of nadir serum asparaginase activity above the level of 0.1 U/mL
  • Asparlas (calaspargase pegol-mknl- IV) is an asparagine specific enzyme approved as a combination therapy for patients with ALL aged 1 month to 21 yr

Ref: The US FDA | Image: WSJ

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions